Actigraphy and Neonatal Abstinence Syndrome

NCT ID: NCT03977545

Last Updated: 2021-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-23

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of our study is to analyse the correlation between actigraphy and Lipsitz scoring system in neonatal opioid abstinence syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neonatal opioid abstinence syndrome occurs after birth when opioids were used by the mother during pregnancy.

Many scoring systems, like Lipsitz scoring system, are used to diagnose and manage neonatal abstinence syndrome but they are subjective. The majority of items in these scores are motor skills items.

Actigraphy allows to measure objectively the newborn motricity. We will analyse the correlation between actigraphy and Lipsitz scoring system in four groups of newborns.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal Abstinence Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newborn with risk of neonatal opioid abstinence syndrome

The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days

Group Type OTHER

Actigraphy

Intervention Type DIAGNOSTIC_TEST

Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Eutrophic term newborn

The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days

Group Type OTHER

Actigraphy

Intervention Type DIAGNOSTIC_TEST

Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Term newborn with low birth weight

The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days

Group Type OTHER

Actigraphy

Intervention Type DIAGNOSTIC_TEST

Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Eutrophic premature newborn

The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days

Group Type OTHER

Actigraphy

Intervention Type DIAGNOSTIC_TEST

Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Actigraphy

Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newborn \> 32 weeks of gestation + 0 day

Exclusion Criteria

* perinatal asphyxia
* 5- minute Apgar score \< 7
* ante or post-natal brain injury diagnosis
* upper arm motor deficit
* hospitalization in intensive care unit
* neonatal respiratory distress
Maximum Eligible Age

1 Day

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Caen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Caen Univerity Hospital

Caen, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elodie LECORPS

Role: CONTACT

0231272055

Bernard GUILLOIS

Role: CONTACT

0231272564

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lecorps Elodie

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A02290-55

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Neonatal Abstinence Syndrome
NCT01723722 COMPLETED PHASE4